Molecular Sensing exclusively licensed Vanderbilt University’s technology for a biosensor platform based on backscattering interferometry. ForteBio named Joseph D. Keegan, PhD, former president and CEO of Molecular Devices, president and CEO in September. NextGen Sciences named Dr. Mike Pisano, founder of Proteomic Research Services (see IBO 1/31/07), CEO. Precision System Science reported fiscal 2007 sales rose 1.7% to ¥3,698 million ($31.2 million). Operating income declined to a loss of ¥57 million ($500,000) (see IBO 10/15/07). The company forecasts fiscal 2008 revenues of ¥4,000 million ($33.7 million). The company signed agreements with Invitrogen, Beckman Coulter and NanoString Technologies, among others, bringing its total number of OEM partners to nine. Sequenom will develop a third-generation single molecular nucleic acid analysis technology based on an exclusive license from Harvard University. The readout technology for single DNA molecules is based on simultaneous optical probing of multiple nanopores. DeltaDOT received £3 million ($6.1 million) in a fourth round of funding, led by FF&P Private Equity. 454 Life Sciences, a Roche company, and Perlegen will collaborate to conduct a large-scale genetic resequencing of hundreds of DNA samples in order to determine whether a clinical test for drug response can be created. Helicos BioSciences promoted Steve Lombardi to president in October. He retained his position as COO. Akubio, a developer of acoustic biosensor technology, entered administration in September. Baker Tilly Restructuring and Recovery was appointed administrator. Luminex reached a settlement with its spinout Rules Based Medicine (RBM) (see IBO 9/15/02), under which it will receive $12.5 million in cash for a dispute involving the formation of Biophysical Corporation, the retirement of Luminex’s stock ownership in RBM and the grant of additional licensing rights to Luminex.